Bil­lions on the ta­ble, GSK’s Hal Bar­ron antes $120M cash to part­ner with a spe­cial­ist in syn­thet­ic lethal­i­ty

GSK R&D chief Hal Bar­ron has turned to an­oth­er Bay Area biotech for his lat­est on­col­o­gy drug de­vel­op­ment pact, which could to­tal bil­lions for a pre­clin­i­cal deal that starts with $120 mil­lion in cash. And this one speaks di­rect­ly to one of his fa­vorite top­ics: syn­thet­ic lethal­i­ty.

Bar­ron is part­ner­ing with Ideaya Bio­sciences $IDYA for this new al­liance. GSK is hand­ing over $100 mil­lion in up­front cash, plus an­oth­er $20 mil­lion for a chunk of stock.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER